Compound information
- Natural Products
- ZC3646303
- Molecular Formula
- C20H20Cl2N2O3S
- Molecular Weight
- 438.05716886 g/mol
- Structure
-
- IUPAC Name
- (1S,3R)-3-(2,2-dichlorovinyl)-N-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)thiazol-2-yl]-2,2-dimethyl-cyclopropanecarboxamide
- InChI
- InChI=1S/C20H20Cl2N2O3S/c1-20(2)12(9-16(21)22)17(20)18(25)24-19-23-13(10-28-19)11-4-5-14-15(8-11)27-7-3-6-26-14/h4-5,8-10,12,17H,3,6-7H2,1-2H3,(H,23,24,25)/t12-,17+/m0/s1
- InChI Key
- AFFZQAHLBRYCLT-YVEFUNNKSA-N
- SMILES
- CC1(C)[C@@H](C(=O)Nc2nc(-c3ccc4c(c3)OCCCO4)cs2)[C@@H]1C=C(Cl)Cl
- Source
- ZINC000041004283
Warheads
- Cyclopropane
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 28 | Ring Count | 4 |
| Heteroatom Count | 8 | Rotatable Bond Count | 4 |
| Hydrogen Bond Acceptor Count | 5 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 60.45 Å2 | LogP | 5.621 |
| LogS | -6.554 | LogD | 5.003 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.984 | Pgp substrate | 0.001 |
| HIA | 0.959 | F20 % | 0.985 |
| F30 % | 0.785 | Caco-2 | -4.537 |
| MDCK | -4.695 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.003 | PPB | 99.12 |
| VD | 1.563 | Fu | 1.632 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 1.0 | CYP1A2 substrate | 0.631 |
| CYP2A6 substrate | 0.72 | CYP2B6 substrate | 0.816 |
| CYP2C19 inhibitor | 0.932 | CYP2C19 substrate | 0.934 |
| CYP2C8 substrate | 0.677 | CYP2C9 inhibitor | 0.982 |
| CYP2C9 substrate | 1.0 | CYP2D6 inhibitor | 0.011 |
| CYP2D6 substrate | 0.82 | CYP2E1 substrate | 0.543 |
| CYP3A4 inhibitor | 0.948 | CYP3A4 substrate | 1.0 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.064 | CL | 6.64 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.156 | Hepatotoxicity | 0.73 |
| Mutagenicity | 0.127 | Rat Oral Acute Toxicity | 0.346 |
| FDAMDD | 0.133 | Skin Sensitization | 0.0 |
| Carcinogenicity | 0.048 | Eye Corrosion | 0.008 |
| Eye Irritation | 0.019 | Respiratory Toxicity | 0.979 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 1.417 | IGC50 | 4.385 |
| LC50FM | 6.832 | LC50DM | 6.918 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.619 | NR-AR-LBD | 0.363 |
| NR-AhR | 0.898 | NR-Aromatase | 0.846 |
| NR-ER | 0.743 | NR-ER-LBD | 0.731 |
| NR-PPAR-gamma | 0.864 | SR-ARE | 0.818 |
| SR-ATAD5 | 0.685 | SR-HSE | 0.779 |
| SR-MMP | 0.905 | SR-p53 | 0.83 |
Similar covalent drugs
No similar covalent drugs found for this compound.